Literature DB >> 20190642

The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women's Interagency HIV Study.

Andrea A Howard1, Donald R Hoover, Kathryn Anastos, Xi Wu, Qiuhu Shi, Howard D Strickler, Stephen R Cole, Mardge H Cohen, Andrea Kovacs, Michael Augenbraun, Patricia S Latham, Phyllis C Tien.   

Abstract

BACKGROUND: Opiate use is common in HIV-infected and hepatitis C virus (HCV)-infected individuals, however, its contribution to the risk of diabetes mellitus is not well understood.
METHODS: Prospective study of 1713 HIV-infected and 652 HIV-uninfected participants from the Women's Interagency HIV Study between October 2000 and March 2006. Diabetes defined as fasting glucose > or =126 mg/dL, self report of diabetes medication use, or confirmed diabetes diagnosis. Opiate use determined using an interviewer-administered questionnaire. Detectable plasma HCV RNA confirmed HCV infection.
RESULTS: Current opiate users had a higher prevalence of diabetes (15%) than nonusers (10%, P = 0.03), and a higher risk of incident diabetes (adjusted relative hazard: 1.58, 95% confidence interval: 1.01 to 2.46), after controlling for HCV infection, HIV/antiretroviral therapy status, and diabetes risk factors including age, race/ethnicity, family history of diabetes, and body mass index. HCV infection was also an independent risk factor for diabetes (adjusted relative hazard: 1.61, 95% confidence interval: 1.02 to 2.52). HCV-infected women reporting current opiate use had the highest diabetes incidence (4.83 cases per 100 person-years).
CONCLUSIONS: Among women with or at-risk for HIV, opiate use is associated with increased diabetes risk independently of HCV infection. Diabetic screening should be part of care for opiate users and those infected with HCV.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190642      PMCID: PMC3069645          DOI: 10.1097/QAI.0b013e3181d0c911

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

1.  Oral glucose tolerance and hormonal response in heroin-dependent males.

Authors:  J L Reed; A H Ghodse
Journal:  Br Med J       Date:  1973-06-09

2.  Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3.

Authors:  Takumi Kawaguchi; Takafumi Yoshida; Masaru Harada; Takao Hisamoto; Yumiko Nagao; Tatsuya Ide; Eitaro Taniguchi; Hiroto Kumemura; Shinichiro Hanada; Michiko Maeyama; Shinji Baba; Hironori Koga; Ryukichi Kumashiro; Takato Ueno; Hisanobu Ogata; Akihiko Yoshimura; Michio Sata
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

3.  Morphine induces desensitization of insulin receptor signaling.

Authors:  Yu Li; Shoshana Eitan; Jiong Wu; Christopher J Evans; Brigitte Kieffer; Xiaojian Sun; Roberto D Polakiewicz
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

4.  Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models.

Authors:  Stephen R Cole; Miguel A Hernán; James M Robins; Kathryn Anastos; Joan Chmiel; Roger Detels; Carolyn Ervin; Joseph Feldman; Ruth Greenblatt; Lawrence Kingsley; Shenghan Lai; Mary Young; Mardge Cohen; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

5.  Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users.

Authors:  Andrea A Howard; Robert S Klein; Ellie E Schoenbaum
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

6.  Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS.

Authors:  Ellen M Tedaldi; Katherine Huppler Hullsiek; Carlos D Malvestutto; Roberto C Arduino; Evelyn J Fisher; Paul J Gaglio; Elizabeth R Jenny-Avital; Joseph P McGowan; George Perez
Journal:  Clin Infect Dis       Date:  2003-05-06       Impact factor: 9.079

7.  The metabolic effects of lopinavir/ritonavir in HIV-negative men.

Authors:  Grace A Lee; Tara Seneviratne; Mustafa A Noor; Joan C Lo; Jean-Marc Schwarz; Francesca T Aweeka; Kathleen Mulligan; Morris Schambelan; Carl Grunfeld
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

8.  Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes.

Authors:  Serhat Aytug; David Reich; Lawrence E Sapiro; David Bernstein; Najma Begum
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

9.  The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.

Authors:  Shruti H Mehta; Richard D Moore; David L Thomas; Richard E Chaisson; Mark S Sulkowski
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-15       Impact factor: 3.731

10.  Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.

Authors:  Yoshizumi Shintani; Hajime Fujie; Hideyuki Miyoshi; Takeya Tsutsumi; Kazuhisa Tsukamoto; Satoshi Kimura; Kyoji Moriya; Kazuhiko Koike
Journal:  Gastroenterology       Date:  2004-03       Impact factor: 22.682

View more
  11 in total

1.  Higher CD163 levels are associated with insulin resistance in hepatitis C virus-infected and HIV-infected adults.

Authors:  Michael Reid; Yifei Ma; Rebecca Scherzer; Jennifer C Price; Audrey L French; Michael W Plankey; Carl Grunfeld; Phyllis C Tien
Journal:  AIDS       Date:  2017-01-28       Impact factor: 4.177

Review 2.  Endocrinological aspects of HIV infection.

Authors:  F S Mirza; P Luthra; L Chirch
Journal:  J Endocrinol Invest       Date:  2018-01-08       Impact factor: 4.256

3.  Testosterone and Abnormal Glucose Metabolism in an Inner-City Cohort.

Authors:  Anne K Monroe; Adrian S Dobs; Joseph Cofrancesco; Todd T Brown
Journal:  J Mens Health       Date:  2012-09       Impact factor: 0.537

4.  Immune deficiency could be an early risk factor for altered insulin sensitivity in antiretroviral-naive HIV-1-infected patients: the ANRS COPANA cohort.

Authors:  Faroudy Boufassa; Cécile Goujard; Jean-Paul Viard; Robert Carlier; Bénédicte Lefebvre; Patrick Yeni; Olivier Bouchaud; Jacqueline Capeau; Laurence Meyer; Corinne Vigouroux
Journal:  Antivir Ther       Date:  2012

5.  Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data.

Authors:  Traci R Rieckmann; Nicholas Gideonse; Amanda Risser; Jennifer E DeVoe; Amanda J Abraham
Journal:  J Behav Health Serv Res       Date:  2017-07       Impact factor: 1.505

Review 6.  HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Authors:  Eva A Operskalski; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2011-03       Impact factor: 5.071

Review 7.  Diabetes and HIV: current understanding and future perspectives.

Authors:  Sanjay Kalra; Navneet Agrawal
Journal:  Curr Diab Rep       Date:  2013-06       Impact factor: 4.810

Review 8.  Diabetes mellitus type 2 and abnormal glucose metabolism in the setting of human immunodeficiency virus.

Authors:  Colleen Hadigan; Sarah Kattakuzhy
Journal:  Endocrinol Metab Clin North Am       Date:  2014-09       Impact factor: 4.741

9.  Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population-based cohort study.

Authors:  Line D Rasmussen; Elisabeth R Mathiesen; Gitte Kronborg; Court Pedersen; Jan Gerstoft; Niels Obel
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

10.  Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors.

Authors:  Edana Cassol; Vikas Misra; Alexander Holman; Anupa Kamat; Susan Morgello; Dana Gabuzda
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.